Claire Repellin

Claire Repellin currently serves as Principal Scientist at ORIC Pharmaceuticals Inc., a position held since September 2022. Prior to this, Claire worked as a Scientist at Cairn Biosciences and as a Research Scientist at SRI International, focusing on drug discovery, development of cell-based assays, and immuno-oncology projects, particularly in lung cancer treatment. Previously, Claire held research fellow positions at Dana-Farber Cancer Institute and Mayo Clinic, studying mechanisms of resistance in lung cancer and TGF-beta signaling, respectively. Claire earned a PhD in Molecular Genetics and a Master of Research in Molecular Functions in Disease from the University of Glasgow.